All patients treated with INB-200, in clinical development for the treatment of glioblastoma multiforme , have shown a well-tolerated safety profile and longer than anticipated progression free. | March 17, 2022
OXFORD, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced
BOSTON, Feb. 17, 2022 Yumanity Therapeutics , a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for. | February 17, 2022